WAT Waters Corporation

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.

In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...

Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter performance since 2020, driven largely by enthusiasm for Artificial Intelligence. Nine of the ten largest companies in the Russell Midcap Index […]

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

Waters Corporation has outperformed the Health Care industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Waters stock has put in a strong multi year gain, yet the valuation signals are split, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to upside while the earnings multiple checks lean expensive. Over the past 3 years, Waters has returned about 53%, which puts more pressure on today’s entry price to be well supported by fundamentals. The company’s ability to keep converting its specialized analytical instruments and services into steady cash flow can...

Waters (WAT) stock is back in focus after the company reported Q2 2026 adjusted earnings of $3.05 per share and raised its full year guidance for organic revenue growth and adjusted earnings. At a share price of $413.56, Waters has posted a 30 day share price return of 4.41% and a 90 day share price return of 13.19%. The 1 year total shareholder return of 38% and 3 year total shareholder return of 53% point to building momentum supported by upgraded guidance and recent leadership...

Waters Corporation recently announced that Senior Vice President of the Waters Analytical Sciences Division, Robert L. Carpio III, resigned in August 2026, with Tina Wu, previously head of the Materials Sciences Division and President, China, stepping into the role after more than two decades of global leadership experience at DuPont. Around the same time, Waters reported very large year-over-year revenue growth in the second quarter of 2026 and raised its full-year guidance, underlining the...

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.

Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers.

Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The

Organic growth accelerated to 9% as acquired units and legacy markets recovered.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve

Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...

Apple's fiscal Q3 showed broad iPhone, Mac and Services demand, but rising costs, supply constraints and policy risks cloud the near-term outlook.

WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.

Moby summary of Waters Corporation's Q2 2026 earnings call

Waters Corp (WAT) delivered a 9% constant currency organic revenue beat in Q2 2026, prompting an upward revision to full-year guidance despite FX headwinds.

Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.

Waters (WAT) delivered earnings and revenue surprises of +1.33% and +1.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instruments company Waters Corporation (NYSE:WAT) announced better-than-expected revenue in Q2 CY2026, with sales up 113% year on year to $1.65 billion. The company expects next quarter’s revenue to be around $1.75 billion, close to analysts’ estimates. Its non-GAAP profit of $3.05 per share was 1.4% above analysts’ consensus estimates.

Scientific instruments company Waters Corporation (NYSE:WAT) will be reporting results this Tuesday before the bell. Here’s what to expect.

Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Waters (WAT) is back on investor radars after recent trading highlighted its role in analytical instruments and software used across pharmaceuticals, chemicals, and environmental testing. This has prompted a closer look at its valuation and fundamentals. See our latest analysis for Waters. At a share price of US$374.68, Waters has seen short term volatility, with the share price slipping 2.02% over the last day but gaining 24.98% over 90 days. The 1 year total shareholder return of 23.68%...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Waters Corporation (NYSE:WAT) and its peers.

Waters Corporation will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.